Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Negócios · 10/05/20241 min de leitura
Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors
Tradução automática local · Idioma original da fonte
Resumo
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to McSAF Inside Oncology SAS ("McSAF Inside Oncology") located in Tours, France.
Idioma original da fonte: Federal Register — Health and Human ServicesAbrir o comunicado original →